Perampanel Can Cause Bradycardia
Yes, perampanel can cause bradycardia, though this is not a commonly emphasized adverse effect in the FDA labeling. The evidence from pediatric overdose cases consistently demonstrates bradycardia as a significant cardiovascular manifestation of perampanel toxicity 1, 2, 3.
Evidence from Clinical Cases
The most compelling evidence comes from documented overdose cases:
- A 20-month-old who ingested 8 mg of perampanel developed hypotension and bradycardia requiring fluid resuscitation, with intermittent bradycardia persisting for 32 hours after ingestion 2
- A 2-year-old female who ingested 0.77 mg/kg developed bradycardia after 6 hours, requiring pediatric intensive care unit admission 3
- A case report specifically noted bradycardia as part of the toxicity profile, alongside central nervous system depression and prolonged coma 1
FDA Labeling Information
The FDA label for perampanel does NOT list bradycardia as a specific adverse effect in its standard dosing sections 4. However, the thorough QT study demonstrated that perampanel did not cause clinically significant QT prolongation, suggesting the drug was evaluated for cardiac effects 4.
Clinical Context and Mechanism
The bradycardia appears to be:
- Dose-dependent: More prominent in overdose situations
- Part of a broader toxicity syndrome: Occurring alongside hypotension, central nervous system depression, and prolonged coma
- Potentially responsive to stimulation and fluid resuscitation 2
Important Caveats
The bradycardia risk must be distinguished from the well-established bradycardia caused by other cardiac medications discussed extensively in the guideline evidence (beta-blockers, calcium channel blockers, digoxin, amiodarone) 5, 6, 7, 8, 9, 10, 11, 12, 13. These guidelines address bradycardia from cardiovascular drugs, not antiepileptic medications like perampanel.
Monitor for bradycardia when initiating perampanel, particularly in patients taking other medications that can slow heart rate (beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, or antiarrhythmic drugs). The combination could have additive effects on heart rate, though this specific interaction has not been formally studied.
Given perampanel's extremely long half-life of 105 hours 4, any bradycardic effects may be prolonged and require extended monitoring, as demonstrated in the pediatric cases where bradycardia persisted for over 30 hours 2.